Citius Pharmaceuticals (CTXR) announced that it has completed the previously announced merger of its oncology subsidiary with TenX Keane Acquisition (TENK), a publicly traded special purpose acquisition company. The combined company will operate as “Citius Oncology” and is expected to begin trading on August 13 on the Nasdaq stock exchange under the ticker symbol “CTOR.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
- TenX Keane addresses trading halt, continues toward combination closing
- Biotech Alert: Searches spiking for these stocks today
- Citius Pharmaceuticals announces FDA approval of Lymphir
- TenX Keane shareholders approve merger with Citius subsidiary